Prostate Cancer
Androgen deprivation decreases prostate specific antigen in the absence of tumor: Implications for interpretation of PSA results - Abstract
February 12, 2014
Three-year follow-up of 12 patients with prostate cancer treated with monthly degarelix in a phase II clinical trial - Abstract
February 12, 2014
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15) - Abstract
February 12, 2014
Target volume coverage and dose to organs at risk in prostate cancer patients : Dose calculation on daily cone-beam CT data sets - Abstract
February 12, 2014
Metformin in chemotherapy-naive castration-resistant prostate cancer: A multicenter phase 2 trial (SAKK 08/09) - Abstract
February 12, 2014
Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases - Abstract
February 12, 2014
Volumetric modulated arc therapy for prostate cancer patients with hip prosthesis - Abstract
February 12, 2014
Focal therapy and prostate cancer - Abstract
February 11, 2014
Urinary continence in laparoscopic radical prostatectomy with bladder neck preservation - Abstract
February 11, 2014
Helical intensity-modulated radiotherapy of the pelvic lymph nodes with integrated boost to the prostate bed - Initial results of the PLATIN 3 trial - Abstract
February 11, 2014
Androgen deprivation therapy improves pneumoperitoneum time during laparoscopic radical prostatectomy in Japanese patients with enlarged prostates - Abstract
February 11, 2014
OncoGenex announces target number of events reached in phase 3 SYNERGY trial of custirsen in metastatic castrate-resistant prostate cancer
February 11, 2014
It ain't what you do, it's the way you do it: Five golden rules for transforming prostate-specific antigen screening - Abstract
February 11, 2014